Clinical Trials Logo

Sarcoma, Ewing clinical trials

View clinical trials related to Sarcoma, Ewing.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05100368 Completed - Sarcoma, Ewing Clinical Trials

The Prognostic Value of Serum Biomarkers in Ewing's Sarcoma

Start date: April 2, 2021
Phase:
Study type: Observational

Extraction of laboratory data from blood tests prior to surgical and chemotherapy and other histological, clinical and instrumental data related to the patient's history from the digitized medical Digitized medical records and analysis of the same. The medical records of 1000 patients from January 1, 2000, until December 31, 2020

NCT ID: NCT05093322 Completed - Lymphoma Clinical Trials

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Start date: November 30, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of surufatinib, thereby identifying the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of surufatinib administered in combination with gemcitabine in pediatric patients with recurrent or refractory solid tumors or lymphoma. The study will be conducted in 2 parts.

NCT ID: NCT05024253 Completed - Osteosarcoma Clinical Trials

Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements.

Start date: August 2, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to investigate whether previously reported benefit of Tranexamic acid in pediatric orthopedic surgeries could be recapitulated in bone tumor surgeries or not through a double blinded randomized controlled trial done in children cancer hospital 57357.

NCT ID: NCT04956198 Completed - Osteosarcoma Clinical Trials

Drug Sensitivity and Mutation Profiling

Start date: November 17, 2020
Phase:
Study type: Observational

This study is a prospective, non-randomized observational study. Freshly isolated tumor cells will be tested for chemosensitivity to the standard of care drugs as single agents and in combinations using state-of-the-art viability assay designed for ex-vivo high-throughput drug sensitivity testing (DST). In addition, the genetic profile of the tumor will be obtained from the medical records and correlated with drug response.

NCT ID: NCT04854018 Completed - Rhabdomyosarcoma Clinical Trials

Indo-cyanine Green (ICG) in Paediatric Oncology MIS

Start date: April 30, 2021
Phase: Phase 4
Study type: Interventional

Indo-cyanine green (ICG) is a dye that has been used for a variety of adult and paediatric uses since 1956. Over the past few years, near infrared (NIRF) technology has been developed which allow is use as a fluorescence agent during surgery. It has been used increasingly in the field of adult oncology surgery and has been shown to increase the efficacy of this surgery. The aim of this study is to evaluate the use of NIRF and ICG during specific minimally invasive surgery (MIS) procedures within paediatric oncology surgery. Their use will complement existing surgical techniques rather than replace them. Given the published advantages in adults this study aims to provide evidence of feasibility in the paediatric patients with cancer.

NCT ID: NCT04661852 Completed - Clinical trials for Refractory Osteosarcoma

Cabozantinib With Topotecan-Cyclophosphamide

Start date: December 23, 2020
Phase: Phase 1
Study type: Interventional

This research study is a clinical trial of a new combination of drugs as a possible treatment for relapsed/refractory Ewing sarcoma and/or osteosarcoma. - The names of the drugs are: - Cabozantinib - Topotecan - Cyclophosphamide - The names of the non-investigational supportive care drugs are: - Filgrastim, pegfilgrastim, or a related growth factor.

NCT ID: NCT04300179 Completed - Neoplasms Clinical Trials

Ewing Sarcoma Family of Tumors (ESFT): A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt

Start date: July 7, 2020
Phase:
Study type: Observational

The aim of this study is to identify demographic & disease characteristics in pediatric oncology patients diagnosed with Ewing Sarcoma Family of Tumors (ESFT) & treatment outcomes in these patients.

NCT ID: NCT04129151 Completed - Ewing Sarcoma Clinical Trials

Palbociclib + Ganitumab In Ewing Sarcoma

Start date: December 5, 2019
Phase: Phase 2
Study type: Interventional

This research study is designed to study the combination of two drugs, palbociclib and ganitumab, as a potential treatment for Ewing sarcoma. The names of the study drugs involved in this study are: - Palbociclib - Ganitumab

NCT ID: NCT03968471 Completed - Clinical trials for Ewing Sarcoma of Bone

Chemotherapy-induced Necrosis in Ewing Sarcoma

Start date: May 13, 2019
Phase:
Study type: Observational

This is single institution cases series review of histological and clinical data

NCT ID: NCT03542097 Completed - Clinical trials for Ewing Sarcoma Family of Tumors

Assessment of MGMT Promoter Methylation in Advanced Ewing Sarcoma Treated With Temozolomide and Irinotecan

MGMTLiberati
Start date: April 15, 2014
Phase:
Study type: Observational

This is a biological study in patients with advanced Ewing Sarcoma who received, according, clinical practice, temozolomide and irinotecan The O6-methylguanine-DNA methyltransferase (MGMT) methylation status, will be correlated with the disease clinical data and with the disease response